[Clinical study on norfloxacin in pediatrics].
Pediatric infections were treated with norfloxacin (NFLX), a pyridonecarboxylic acid antibiotic developed by Kyorin Co., Ltd., to investigate its clinical efficacy. 1. Thirteen patients were treated with NFLX. These patients included of 5 with Campylobacter enteritis, 4 with Salmonella enteritis, 3 with dysentery and 1 with acute enteritis. 2. Of 14 pathogens identified, complete eradications were observed with 13 strains and partial eradication was seen in 1 case. Thus, overall eradication rate was 92.9%. 3. These were no symptoms nor abnormal laboratory findings which indicated an occurrence of side effect due to the NFLX treatment.
Minamitani
M
M
Department of Infectious Diseases, Tokyo Metropolitan, Komagome, Hospital.
Hachimori
K
K
Kaneda
K
K
D000293:Adolescent; D000367:Age Factors; D002169:Campylobacter Infections; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004405:Dysentery, Bacillary; D004751:Enteritis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D012480:Salmonella Infections
D009643:Norfloxacin